Heart health-focused Cleerly closed a Series C financing round of $192 million. The new funding brings the total raised by the health care company to $248 million, which includes a Series B round in 2021.
The oversubscribed funding round was led by funds and accounts advised by T. Rowe Price Associates and T. Rowe Price Investment Management, and Fidelity Management and Research Company. They are joined by additional investors spanning the health care, pharmaceutical and technology sectors, including Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, and Novartis. Cleerly’s existing investors also participated in the financing and include Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures and DigiTx Partners.
Cleerly enables comprehensive phenotyping of coronary artery disease. Read more.
